目的探讨乳腺癌组织中Tuberin和磷酸化Girdin(p-Girdin)蛋白的表达及其与乳腺癌临床病理特征和分子分型的关系。方法应用免疫组化Envision法检测102例乳腺非特殊型浸润性导管癌、52例乳腺导管原位癌、31例乳腺纤维腺瘤组织中Tuberin及p-Girdin蛋白的表达情况。结果 Tuberin在乳腺非特殊型浸润性导管癌、乳腺导管原位癌、乳腺纤维腺瘤组织中的阳性表达率分别为33.3%、59.6%和77.4%,差异有统计学意义(P<0.05)。Tuberin与乳腺非特殊型浸润性导管癌患者年龄、病理学分期、组织学分级、肿瘤大小、淋巴结转移、雌激素受体(ER)、孕激素受体(PR)、人表皮生长因子受体(HER-2)无关(P>0.05)。Tuberin在管腔A型、管腔B型、HER-2(+)型和三阴性乳腺非特殊浸润性导管癌中的阳性表达率分别为34.0%、40.0%、31.3%和21.4%,差异无统计学意义(P>0.05)。p-Girdin在乳腺非特殊型浸润性导管癌、乳腺导管原位癌和乳腺纤维腺瘤组织中的阳性表达率分别为64.7%、38.4%和22.6%,差异有统计学意义(P<0.05)。p-Girdin与乳腺非特殊型浸润性导管癌的病理学分期、淋巴结转移数及HER-2状态呈正相关(P<0.05),与患者年龄、组织学分级、肿瘤大小、ER、PR无相关性(P>0.05)。p-Girdin在乳腺非特殊浸润性导管癌的四种分子分型中的阳性表达率分别为57.4%、92.0%、62.5%和42.9%,差异有统计学意义(P>0.05)。Tuberin与p-Girdin在乳腺非特殊浸润性导管癌中的表达无关(P>0.05)。结论乳腺癌组织中Tuberin的表达明显降低,可能具有抑制乳腺癌增殖、侵袭、转移的作用,而p-Girdin的表达可能与乳腺癌的恶性进展密切相关。 Objective To investigate the expression of Tuberin and phosphorylated Girdin (p-Girdin) in breast cancer and its relationship with clinicopathological features and molecular typing of breast cancer. Methods The expressions of Tuberin and p-Girdin protein in 102 cases of breast non-specific invasive ductal carcinoma, 52 cases of ductal carcinoma in situ and 31 cases of breast fibroadenoma were detected by immunohistochemical Envision method. Results The positive rates of Tuberin in breast non-specific invasive ductal carcinoma, ductal carcinoma in situ and breast fibroadenoma were 33.3%, 59.6% and 77.4%, respectively, with statistical significance (P <0.05). Tuberin and breast non-specific invasive ductal carcinoma patients age, histological grade, histological grade, tumor size, lymph node metastasis, estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor HER-2) (P> 0.05). The positive rates of Tuberin in luminal A, luminal B, HER-2 (+) and triple negative breast non-special invasive ductal carcinomas were 34.0%, 40.0%, 31.3% and 21.4%, respectively, with no difference Statistical significance (P> 0.05). The positive rates of p-Girdin in breast non-specific invasive ductal carcinoma, ductal carcinoma in situ and breast fibroadenoma were 64.7%, 38.4% and 22.6%, respectively, with significant difference (P <0.05) . There was a positive correlation between the expression of p-Girdin and pathological stage, lymph node metastasis and HER-2 status (P <0.05) in breast non-specific invasive ductal carcinoma and no correlation with age, histological grade, tumor size, ER and PR (P> 0.05). The positive rates of p-Girdin in the four molecular types of breast non-specific invasive ductal carcinoma were 57.4%, 92.0%, 62.5% and 42.9%, respectively, with statistical significance (P> 0.05). The expression of Tuberin and p-Girdin in breast non-special invasive ductal carcinoma had no correlation (P> 0.05). Conclusion The expression of Tuberin in breast cancer tissues is obviously decreased, which may inhibit the proliferation, invasion and metastasis of breast cancer. The expression of p-Girdin may be closely related to the malignant progression of breast cancer.